相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
Jennifer M. Logue et al.
HAEMATOLOGICA (2021)
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
Michael D. Jain et al.
BLOOD (2021)
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Elise A. Chong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
Julien Edeline et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma
Charlotte Elizabeth Graham et al.
LEUKEMIA (2021)
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
Seshu Tyagarajan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
CAR T-Cell Therapy: Clinical Outcomes, Patient Selection and Financial Metrics with Tisagenlecleucel and Axicabtagene Ciloleucel, a Single Center Experience
Nathan Denlinger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Pierre Sesques et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Caron A. Jacobson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Chelsea C. Pinnix et al.
BLOOD ADVANCES (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
Frederick L. Locke et al.
BLOOD ADVANCES (2020)
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Marcelo C. Pasquini et al.
BLOOD ADVANCES (2020)
Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
Gary H. Lyman et al.
JAMA NETWORK OPEN (2020)
Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial
Richard T. Maziarz et al.
BLOOD ADVANCES (2020)
Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial
Stephen J. Schuster et al.
BLOOD ADVANCES (2020)
CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS
V. Bachanova et al.
HEMATOLOGICAL ONCOLOGY (2019)
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
John K. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu et al.
MOLECULAR CANCER (2019)
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
Jason R. Westin et al.
BLOOD (2019)
A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Peter A. Riedell et al.
BLOOD (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Anna Wolska-Washer et al.
DRUG SAFETY (2019)
Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma
Matthew J. Frank et al.
BLOOD (2019)
Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
Marcelo C. Pasquini et al.
BLOOD (2019)
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas
Jeremy S. Abramson et al.
BLOOD (2019)
Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Michael D. Jain et al.
BLOOD (2019)
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
Veronika Bachanova et al.
BLOOD (2019)
Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture
Seshu Tyagarajan et al.
CYTOTHERAPY (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
CD19-directed CAR T cells gain traction
Stephen J. Schuster
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma
Melanie D. Whittington et al.
JAMA NETWORK OPEN (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
Inmaculada Hernandez et al.
JAMA ONCOLOGY (2018)
Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.
Frederick Lundry Locke et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
Loretta J. Nastoupil et al.
BLOOD (2018)
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel
Stephen J. Schuster et al.
BLOOD (2018)
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
Caron A. Jacobson et al.
BLOOD (2018)
Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study
Lihua E. Budde et al.
BLOOD (2018)
TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
M. Lia Palomba et al.
BLOOD (2018)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
Karen Thudium Mueller et al.
BLOOD (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells (vol 44, pg 380, 2016)
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
分享论文
